Xylem Inc. (XYL) Analyst Forecast

NYSE Currency in USD Disclaimer

Stock Price

$127.44

$2.08

(1.66%)

Day's range

$126

$127.64

Consensus Rating

Hold

Based on 28 Analyst Ratings
Consensus Price Target

$141.83

11.29% Upside

Recent Analyst Forecasts and Stock Ratings

Date	Brokerage Firm	Analyst Name	Price Target	Price when Posted	Upside/Downside on Report Date	Details
08/13/2024	UBS	Damian Karas	$165.00	$127.50	29.41%
07/31/2024	Robert W. Baird	Michael Halloran	$170.00	$133.48	27.36%
05/31/2024	Oppenheimer	Bryan Blair	$152.00	$139.40	9.04%
05/29/2024	Argus Research	John Eade	$165.00	$140.36	17.55%
05/03/2024	Mizuho Securities	Brett Linzey	$135.00	$135.99	-0.73%
05/03/2024	RBC Capital	Deane Dray	$162.00	$135.99	19.13%
05/03/2024	Robert W. Baird	Michael Halloran	$155.00	$135.99	13.98%
04/08/2024	Wolfe Research	Brad Hewitt	$143.00	$128.27	11.48%
04/04/2024	RBC Capital	Deane Dray	$153.00	$127.25	20.24%
08/18/2023	Stifel Nicolaus	Nathan Jones	$133.00	$99.80	33.27%
11/15/2022	Atlantic Equities	Richard Radbourne	$129.00	$112.13	15.05%
11/21/2021	Loop Capital Markets	Scott Graham	$120.00	$127.19	-5.65%
11/11/2021	Argus Research	John Eade	$150.00	$129.82	15.54%
08/03/2021	Citigroup	Andrew Kaplowitz	$131.00	$125.70	4.22%
05/04/2021	Goldman Sachs	Brian K. Lee	$107.00	$116.20	-7.92%

Xylem Inc. Frequently Asked Questions

What analysts cover Xylem Inc.?

Xylem Inc. has been rated by research analysts at UBS, Robert W. Baird, Oppenheimer, Argus Research, Mizuho Securities, RBC Capital in the past 90 days.

×

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In

Email Address

or

download app using google store

Continue with Google

download app using apple

Continue with Apple

By signing in you agree to our terms of service and privacy policy.

Don't have an account? Sign up

Email Verification

An email with a verification code has been sent to your email address.

Verification Code / OTP

Didn't receive the code?

Welcome to Stocks.News!

or

google app download

Continue with Google

ios app download

Continue with Apple

By signing up you agree to our terms of service and privacy policy.

Already have an account? Log in

Create Your Account

Name

Email Address

By signing up you agree to our terms of service and privacy policy.

Already have an account? Log in

Email Verification

An email with a verification code has been sent to your email address.

Verification Code / OTP

Didn't receive the code?